

CONSOLIDATED					Sr. No.	Particulars	COMPANY				
Rupees in Lacs [except for share data]							Rupees in Lacs [except for share data]				
3 Months Period ended on September 30, 2010 [Unaudited]	Corresponding 3 Months Period ended on September 30, 2009 [Unaudited]	6 Months Period ended on September 30, 2010 [Unaudited]	Corresponding 6 Months Period ended on September 30, 2009 [Unaudited]	Previous accounting Year ended on March 31, 2010 [Audited]			3 Months Period ended on September 30, 2010 [Unaudited]	Corresponding 3 Months Period ended on September 30, 2009 [Unaudited]	6 Months Period ended on September 30, 2010 [Unaudited]	Corresponding 6 Months Period ended on September 30, 2009 [Unaudited]	Previous accounting Year ended on March 31, 2010 [Audited]
112,135	92,500	218,954	181,459	361,423	1	Sales & Income from operations :	58,385	48,898	114,629	95,899	185,491
1,503	1,242	2,813	2,170	4,005	A	Gross Sales	882	747	1,703	1,221	2,198
110,632	91,258	216,141	179,289	357,418	B	Less : Excise Duty	57,503	48,151	112,926	94,678	183,293
1,037	3,320	8,906	5,643	11,267	C	Net Sales	16,400	16,245	39,314	29,292	59,196
111,669	94,578	225,047	184,932	368,685	D	Other Income from Operations	73,903	64,396	152,240	123,970	242,489
					E	Total sales and other income from operations					
(1,959)	(1,654)	(3,651)	(4,273)	(11,334)	2	Expenditure :	(2,900)	2,279	(3,230)	2,020	(1,080)
29,786	22,845	56,250	44,910	97,889	A	Increase [-] / Decrease [+] in stock in trade & work in progress	20,836	16,744	39,857	32,561	70,548
7,587	9,010	15,409	17,842	31,280	B	Consumption of materials	3,746	2,309	6,799	4,623	7,319
13,651	11,120	26,418	21,366	44,059	C	Purchase of traded goods	8,469	6,724	16,997	13,213	27,790
3,044	3,112	6,183	6,074	13,389	D	Employees cost	2,349	2,204	4,753	4,301	9,004
38,119	32,692	76,401	64,149	125,924	E	Depreciation, Amortisation & Impairment	23,880	21,050	47,904	40,306	76,924
					F	Other Expenditure	56,380	51,310	113,080	97,024	190,505
90,228	77,125	177,010	150,068	301,207	G	Total Expenditure	17,523	13,086	39,160	26,946	51,984
21,441	17,453	48,037	34,864	67,478	3	Profit from Operations before Other Income, Interest & Exceptional Items [1 - 2]	2,368	1,110	3,942	2,374	4,351
385	411	672	833	1,591	4	Other Income	19,891	14,196	43,102	29,320	56,335
21,826	17,864	48,709	35,697	69,069	5	Profit before Interest & Exceptional Items [3 + 4]	923	968	2,168	2,322	4,263
1,792	2,055	4,032	4,349	8,092	6	A Interest & financial charges	(182)	158	10	322	45
(188)	253	727	394	122	B	Gain [-] / Loss [+] on Exchange Rate Fluctuations on Foreign Currency Loans	741	1,126	2,178	2,644	4,308
1,604	2,308	4,759	4,743	8,214	C	Total Financial cost	19,150	13,070	40,924	26,676	52,027
20,222	15,556	43,950	30,954	60,855	7	Profit after Interest but before Exceptional Items [5 - 6]	0	0	0	0	0
0	(258)	0	(350)	(464)	8	Exceptional Items [+] Income / [-] Expense	19,150	13,070	40,924	26,676	52,027
20,222	15,298	43,950	30,604	60,391	9	Profit [+] / Loss [-] from Ordinary Activities before tax [7 + 8]	990	630	2,900	1,980	1,700
2,539	1,756	5,916	4,180	7,407	10	Tax expense	18,160	12,440	38,024	24,696	50,327
17,683	13,542	38,034	26,424	52,984	11	Net Profit [+] / Loss [-] from Ordinary Activities after tax [9 - 10]	0	0	0	0	0
0	0	0	0	0	12	Extraordinary items [net of tax expense]	18,160	12,440	38,024	24,696	50,327
17,683	13,542	38,034	26,424	52,984	13	Net Profit [+] / Loss [-] for the period [11 - 12]	0	0	0	0	0
(599)	(350)	(1,032)	(753)	(2,470)	14	Adjustments on consolidation [+] Income / [-] Expense	18,160	12,440	38,024	24,696	50,327
17,084	13,192	37,002	25,671	50,514	15	Net Profit [+] / Loss [-] for the period [13 + 14]	10,237	6,824	10,237	6,824	6,824
10,237	6,824	10,237	6,824	6,824	16	Paid-up equity share capital [Face Value Rs. 5 /-]					155,390
				156,030	17	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year					
8.34	6.44 *	18.07	12.54 *	24.67 *	18	Earnings Per Share [EPS] [For the period - not Annualised]:	8.87	6.08 *	18.57	12.06 *	24.58 *
8.34	6.44 *	18.07	12.54 *	24.67 *	A	Basic and Diluted EPS before Extraordinary Items [Rs.]	8.87	6.08 *	18.57	12.06 *	24.58 *
					B	Basic and Diluted EPS after Extraordinary Items [Rs.]					
51,610,474	34,406,982	51,610,474	34,406,982	34,406,982	19	Public shareholding :	51,610,474	34,406,982	51,610,474	34,406,982	34,406,982
25.21%	25.21%	25.21%	25.21%	25.21%		- Number of shares	25.21%	25.21%	25.21%	25.21%	25.21%
						- Percentage of Shareholding					
					20	Promoters and Promoter group Shareholding :					
					A	Pledged / Encumbered :					
						- Number of Shares	NII	NII	NII	NII	NII
						- Percentage of shares [as a % of the total shareholding of promoters and promoter group]	N.A.	N.A.	N.A.	N.A.	N.A.
						- Percentage of shares [as a % of the total share capital of the company]	N.A.	N.A.	N.A.	N.A.	N.A.
153,138,046	102,092,031	153,138,046	102,092,031	102,092,031	B	Non-encumbered :	153,138,046	102,092,031	153,138,046	102,092,031	102,092,031
100%	100%	100%	100%	100%		- Number of Shares	100%	100.00%	100%	100%	100.00%
74.79%	74.79%	74.79%	74.79%	74.79%		- Percentage of shares [as a % of the total shareholding of promoters and promoter group]	74.79%	74.79%	74.79%	74.79%	74.79%
						- Percentage of shares [as a % of the total share capital of the company]					

Notes :

- [1] The above results for the quarter 30, 2010 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on October 19, 2010.
- [2]* Earning per share in item 1' six months period ended on September 30, 2009 & previous accounting year ended on March 31, 2010 is calculated taking into account the alls issued by the company, to make the figures comparable.
- [3] The changes in Investmente as under :
- | | |
|----------------------------------|--------------|
| Zydus BSV Pharmaial Investment] | Rs. 110 Lacs |
| Zydus Wellness Lintment] | Rs. 55 Lacs |
- [4] During the quarter, the Cor subsidiary companies in Mexico namely – (1) Zydus Pharmaceuticals Mexico S.A. de C.V. and (2) Zydus Pharmaceuticals Mexico Sei
- [5] The status of investor compy
- Pending at the beginning ovised and disposed off during the quarter - 17, pending at the end of the quarter - Nil
- [6] The Company has one searpharmaceuticals".

D		Sr. No.	Particulars	COMPANY		
I				Rupees in Lacs		
6 Month Period ended on September 30, 2010 [Unaudited]	Previous accounting Year ended on March 31, 2010 [Audited]			6 Months Period ended on September 30, 2010 [Unaudited]	Corresponding 6 Months Period ended on September 30, 2009 [Unaudited]	Previous accounting Year ended on March 31, 2010 [Audited]
		1	Shareholders' Funds :			
10,	6,824	A	Capital	10,237	6,824	6,824
189,	156,030	B	Reserves and Surplus	190,011	141,186	155,390
109,	109,054	2	Loan Funds	60,257	77,376	59,413
5,	3,916	3	Minority Interest	0	0	0
11,	11,407	4	Deferred Tax Liability / (Asset)	11,804	12,594	11,494
325,	287,231	5	Total Sources of Funds	272,309	237,980	233,121
204,	193,262	6	Fixed Assets	114,391	103,140	109,329
2,	2,069	7	Investments	68,371	63,466	59,890
		8	Current Assets, Loans and Advances :			
83,	75,040	A	Inventories	45,058	34,664	38,083
61,	46,677	B	Sundry Debtors	49,301	43,944	40,082
26,	25,072	C	Cash and Bank Balances	3,054	4,217	2,822
36,	30,704	D	Loans and Advances	44,498	29,616	36,274
83,	67,100	9	Less : Current Liabilities and Provisions			
6,	19,509	A	Liabilities	47,796	36,977	38,308
(	1,016	B	Provisions	4,244	4,977	15,167
325,	287,231	10	Foreign Currency Monetary Items Translation Difference Account	(324)	887	116
		11	Total Application of Funds	272,309	237,980	233,121

For Cadila Healthcare Limited,

Pankaj R. Patel
Chairman & Managing Director

Ahmedabad, October 19, 2010.